PMID- 27435350
OWN - NLM
STAT- MEDLINE
DCOM- 20170410
LR  - 20220408
IS  - 0867-7077 (Print)
IS  - 0867-7077 (Linking)
VI  - 84
IP  - 4
DP  - 2016
TI  - The effect of omalizumab on eosinophilic inflammation of the respiratory tract in 
      patients with allergic asthma.
PG  - 232-43
LID - 10.5603/PiAP.2016.0029 [doi]
AB  - Bronchial asthma is characterised by high levels of immunoglobulin E (IgE) and 
      overproduction of pro-inflammatory cytokines, including interleukins IL-4, IL-13 
      and IL-5 needed for, amongst other things, the production of IgE and the 
      differentiation, maturation, migration and survival of eosinophils. Eosinophils 
      are one of the most important cells in allergic inflammation. Their presence in 
      tissue is linked to the persistence of inflammatory infiltrate, tissue damage and 
      remodelling. Although these cells are very sensitive to corticosteroids, some 
      asthmatic patients do not respond to high doses of these drugs, even when 
      administered systemically. Transbronchial biopsies and bronchoalveolar lavage 
      performed in patients with steroid-resistant asthma have demonstrated higher 
      levels of eosinophils and Th2-type cytokines (IL-4 and IL-5) compared to 
      steroid-sensitive patients. Clinical studies have confirmed that the very 
      effective treatment in these cases is therapy with omalizumab - an anti-IgE 
      monoclonal antibody. The paper discusses the efficacy of omalizumab in reducing 
      eosinophil number in peripheral blood and in the airways of asthmatic patients 
      based on basic, clinical, observational studies and case reports. The 
      significance of omalizumab therapy in asthma control and mechanisms that regulate 
      the effects of omalizumab on eosinophils are evaluated.
FAU - Kuprys-Lipinska, Izabela
AU  - Kuprys-Lipinska I
AD  - ikuprys@wp.pl.
FAU - Molinska, Katarzyna
AU  - Molinska K
FAU - Kuna, Piotr
AU  - Kuna P
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Poland
TA  - Pneumonol Alergol Pol
JT  - Pneumonologia i alergologia polska
JID - 9302892
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Cytokines)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Asthma/*drug therapy/*immunology
MH  - Cytokines/blood
MH  - Eosinophilia/*blood
MH  - Eosinophils/*drug effects/*immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Inflammation/drug therapy
MH  - Lymphocyte Count
MH  - Male
MH  - Omalizumab/adverse effects/pharmacokinetics/*therapeutic use
MH  - Respiratory System/*immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - allergic asthma
OT  - eosinophilic inflammation
OT  - eosinophils
OT  - omalizumab
EDAT- 2016/07/21 06:00
MHDA- 2017/04/11 06:00
CRDT- 2016/07/21 06:00
PHST- 2016/07/14 00:00 [received]
PHST- 2016/07/21 06:00 [entrez]
PHST- 2016/07/21 06:00 [pubmed]
PHST- 2017/04/11 06:00 [medline]
AID - VM/OJS/J/48135 [pii]
AID - 10.5603/PiAP.2016.0029 [doi]
PST - ppublish
SO  - Pneumonol Alergol Pol. 2016;84(4):232-43. doi: 10.5603/PiAP.2016.0029.